Phase 3 N=10 Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma
Asthma
Primary: The Rate of Number of Subjects Whose PC20 is Less Than 8 mg/mL — 7 percentage of the subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=111 Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 89.2 percentage of participants
Phase 2 N=55 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Hepatorenal Syndrome
Primary: Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide — 36.0; 11.9; 15.7; 10.5 hours
Phase 2 N=123 Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 12.7; 16.7 Percentage of participants — p=0.204
Phase 1 N=26 MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
Allergic Rhinitis · Allergic Rhinoconjunctivitis
Primary: Change From Baseline in D. Farinae HDM-specific IgG4 Antibodies in Serum at 12 Weeks (Part 2) — 0.392; 0.166 Fold Change — p=0.003
N/A N=649 Prevenar13 Post Market Surveillance
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Within 7 Days After Vaccination 1 — 68; 1 participants
Phase 1 N=195 Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Nonseasonal
Primary: Percentage of Participants Who Experienced At Least One Adverse Event (AE) — 56.9; 53.8; 43.1 Percentage of participants
Phase 4 N=49 Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
Depression · Bipolar Disorder
Primary: MADRS Improvement Over 6 Weeks — 10.0; 6.7 units on a scale — p=0.48
Phase 3 N=70 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Phase 3 N=222 A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
Plaque Psoriasis
Primary: The Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 44.5; 7.1 percentage of participants — p=<0.001
Phase 3 N=217 A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
Nail Psoriasis · Plaque Psoriasis
Primary: Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 — 3.4; 46.6 percentage of participants…
Phase 3 N=161 A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
Post-Operative Pain
Primary: Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12). — 25.84; 13.14 units on a scale
Phase 2 N=64 Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Lung Cancer
Primary: Objective Response Rate (OR) Where OR=CR+PR: Number of Participants With Responses of Complete Response (CR) and Partial Response (PR) — 3 Participants
Phase 3 N=217 Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Primary Biliary Cirrhosis
Primary: DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo — 47; 10 percentage of participants — p=<0.0001